Objective: To investigate etiological factors in severe mental retardation (SMR). Methods: An etiological study is presented of 512 SMR patients in five specialized institutions in Havana. Results: Prenatal, perinatal and postnatal causes were apparent in 58.0, 24.8 and 11.1% of the patients, respectively; infantile psychosis was determined in only 0.4%. The remaining 5.6% were classified as having SMR of undeterminable origin, i.e. patients with apparently normal pre-, peri- and postnatal histories who had neither dysmorphism nor affected first-degree relatives, and had a normal karyotype and metabolic screen. Among prenatal causes, genetic factors were the most frequent (82.8%), while environmental factors were apparent in only 5.3% of these cases. Of the cases with prenatal genetic etiology, chromosomal aberrations were present in 86.5% (Down syndrome 96.2% and 3.7% other chromosomal aberrations), monogenic disorders in 11.3% [neurocutaneous diseases (32.1%) and fragile X syndrome (25%) were the most frequent], and multifactorial disorders in 2.0%. Thirty-five patients (11.7%) presented multiple congenital anomalies of ‘prenatal unknown’ causes. The latter group may include unidentifiable chromosomal aberrations, uniparental disomy, de novo mutations and multifactorial or teratogenic factors. Conclusion: Accurate determination of the etiology of SMR is important not only for genetic counseling purposes, but also in identifying prenatal events which make infants more vulnerable to perinatal risk factors.

1.
Gustavson KH, Holmgren G, Jonsell R, Son Blomquist HK: Severe mental retardation in children in a northern Swedish county. J Ment Defic Res 1977;21:161–180.
2.
Li S-Y, Tsai Ch-Ch, Chou M-Y, Lin J-K: A cytogenetic study of mentally retarded school children in Taiwan with special reference to the fragile X chromosome. Hum Genet 1988;79:292–296.
3.
Haspeslagh M, Fryns JP, Holvoet M, Collen G, Dierck G, Baeke J, van den Berghe H: A clinical, cytogenetic and familial study of 307 mentally retarded, institutionalized, adult male patients with special interest for fra(X) negative X-linked mental retardation. Clin Genet 1991;39:434–441.
4.
Holmgren G: Urinary metabolic screening of mentally retarded patients from institutions in the northern part of Sweden. Hum Hered 1973;23:548–560.
5.
Sewell AC: An improved thin-layer chromatography method for urinary oligosaccharide screening. Clin Chim Acta 1979;92:411–414.
6.
Hommes FA: Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York, Wiley-Liss, 1991, pp 69–87.
7.
Galjaard H: Genetic Metabolic Diseases: Early Diagnosis and Prenatal Analysis. Amsterdam, Elsevier/North-Holland Biomedical Press, 1980, pp 15–30.
8.
Lantigua-Cruz A, Guerra D, Zarragoitia OL, Viñas C: Deletion (11p) and t(11;21)(q21;q22.1) in a patient with aniridia Wilms Tumor association. Rev Cubana Oftalmol 1989;2:137–147.
9.
McKusick VA: Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders, ed 12, Baltimore, Johns Hopkins University Press, 1998.
10.
Turner G, Robinson H, Laing S, Purvis-Smith S: Preventive screening for the fragile X syndrome. N Engl J Med 1986;315:607–609.
11.
Penrose LS: On the interaction of heredity and environment in the study of human genetics (with special reference to mongolian imbecility). J Genet 1932;25:407–422.
12.
Speed RM, Johnston AW, Evans HJ: Chromosome survey of total population of mentally subnormal in North-East of Scotland. J Med Genet 1976;13:295–306.
13.
Sutherland GR, Murch AR, Gardiner AJ, Carter RF, Wiseman C: Cytogenetic survey of a hospital for the mentally retarded. Hum Genet 1976;34:231–245.
14.
Fryns JP, Kleczkowska A, Kubien E, Van den Berghe H: Cytogenetic findings in moderate and severe mental retardation. A study of an institutionalized population of 1,991 patients. Acta Paediatr Scand Suppl 1984;313:1–23.
15.
Farag TI, al-Awadi SA, el-Badramary MH, Aref MA, Kasrawi B, Krishna Murthy S, el-Khalifa MY, et al: Disease profile of 400 institutionalized mentally retarded patients in Kuwait. Clin Genet 1993;44:329–334.
16.
Pitt D, Rokoz P, Seidurs E: The spectrum of severe mental deficiency. Experiences with 1,400 cases. Aust J Ment Retard 1972;2:40–46.
17.
Giraud F, Mattei JF: Aspects épidémiologiques de la trisomie 21. J Génét Hum 1975;23:1–30.
18.
Gardner RJM, Sutherland GR: Chromosome Abnormalities and Genetic Counseling. New York, Oxford University Press, 1989, p 12.
19.
Butler MG, Singh DN: Clinical and cytogenetic survey of institutionalized mentally retarded patients with emphasis on the fragile-X syndrome. J Intellect Disabil Res 1993;37:131–142.
20.
Mandel J-L, Hagerman R, Froster U, Brown WT, Jenkins EC, Jacobs P, Turner G, Lubs H, Neri G: Fifth international workshop on fragile X and X-linked mental retardation. Am J Med Genet 1992;43:5–27.
21.
Laxova R, Ridler MAC, Bowen-Bravery M: An etiological survey of the severely retarded Hertfordshire children who were born between January 1, 1965 and December 31, 1967. Am J Med Genet 1977;1:75–86.
22.
Dereymaeker AM, Fryns JP, Haegeman J, Deroover J, Van den Berghe H: A genetic-diagnostic survey in an institutionalized population of 158 mentally retarded patients. The Viaene experience. Clin Genet 1988;34:126–134.
23.
Uvebrant P, Hagberg G: Intrauterine growth in children with cerebral palsy. Acta Paediatr 1992;81:407–412.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.